AML
Conference Coverage
Venetoclax plus LDAC tops LDAC alone in AML
Conference Coverage
Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML
Enasidenib with, or after, azacitidine remains a question.
Conference Coverage
First-in-kind anti-CD47 antibody shows promise for MDS and AML treatment
Conference Coverage
VIALE-A confirms survival benefit for venetoclax-azacitidine in hard-to-treat AML
Conference Coverage
Compound CAR T – a double whammy with promise for AML
For the first time, “a compound CAR with two independent CAR units induced remissions in AML.”
Conference Coverage
Risk index stratifies pediatric leukemia patients undergoing HSCT
From the Journals
CD123 may be a marker for residual disease and response evaluation in AML and B-ALL
Feature
EHA webinar addresses treating AML patients with COVID-19
From the Journals
CLAM trial regimen shown safe, effective for r/r AML
High response rates and effective bridge to transplant shown.
From the Journals
COVID-19: Adjusting practice in acute leukemia care
Guidelines
COVID-19: ASTCT provides interim guidelines for transplantation
The American Society for Transplantation and Cellular Therapy document focuses on patient-treatment specifics and donor issues.